Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Drug Name | Mirzotamab clezutoclax |
Trade Name | |
Synonyms | ABBV-155|ABBV 155|ABBV155 |
Drug Descriptions |
Mirzotamab clezutoclax (ABBV-155) is an antibody-drug conjugate (ADC) consisting of a BCL-XL inhibitor linked to a monoclonal antibody targeted against CD276 (B7H3), which may have antitumor activity (J Clin Oncol 39, no. 15_suppl (May 20, 2021) 3015). |
DrugClasses | BCL-XL inhibitor 14 CD276 Antibody 15 |
CAS Registry Number | NA |
NCIT ID | C157279 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Docetaxel + Mirzotamab clezutoclax | Docetaxel Mirzotamab clezutoclax | 0 | 1 |
Docetaxel + Mirzotamab clezutoclax + Paclitaxel | Docetaxel Mirzotamab clezutoclax Paclitaxel | 0 | 0 |
Mirzotamab clezutoclax | Mirzotamab clezutoclax | 0 | 1 |
Mirzotamab clezutoclax + Paclitaxel | Mirzotamab clezutoclax Paclitaxel | 0 | 1 |